title: Pharmacogenomic Testing and Warfarin Management.
abstract: Warfarin has been used for the prevention of thrombosis for more than 50 years and is the most frequently prescribed vitamin K antagonist in North America (Gage & Eby, 2003). Its mode of action is to prevent vitamin K from converting to vitamin KH2, thereby inhibiting clotting factors (Johnson & Cavallari, 2015). Warfarin metabolism is affected by variations in the cytochrome P450 2C9 (CYP2C9) and the vitamin K epoxide reductase complex 1 (VKORC1) genotypes. CYP2C9 affects the drug's pharmacokinetics, or metabolism, whereas VKORC1, the target protein of warfarin, affects the drug's pharmacodynamics, or its impact on cell proteins .
authors: Accountable Care Solutions at Aetna.
authors: Andrea
authors: A
authors: Maluso
mesh_terms: D000925:Anticoagulants / Q000008:administration & dosage*; D065729:Cytochrome P-450 CYP2C9 / Q000235:genetics; D016903:Drug Monitoring / Q000592:standards; D006801:Humans; D010597:Pharmacogenetics; D017410:Practice Guidelines as Topic; D014859:Warfarin / Q000008:administration & dosage*
chemical_list: D000925:Anticoagulants; D014859:Warfarin; D065729:Cytochrome P-450 CYP2C9
keywords: genetic testing; pharmacogenetics; pharmacogenomics; warfarin